Peter Valent

Peter Valent (born 9 October 1962 in Vienna, Austria) is an Austrian hematologist and stem cell researcher. Since 1990 he leads a research group at the Medical University of Vienna. From 2002 he coordinates the European Competence Network on Mastocytosis and since 2008 he is Scientific Director of the Ludwig Boltzmann Institute for Hematology and Oncology of the Ludwig Boltzmann Society in Austria.[1]

Life and education

Valent studied medicine at the Medical University of Vienna and graduated in 1987. He is a specialist in internal medicine and hematology and was promoted to Assistant Professor for Experimental Hematology in 1992 and Associate Professor for Internal Medicine in 1995. Valent visited several universities in Germany as Guest Scientist, including the Institute of Pathology of the University of Tübingen, the University of Schleswig-Holstein (Campus Lübeck) and the LMU Munich.[2]

Scientific contributions

Mast cell research and the classification of mastocytosis

Between 1989 and 1999 Valent examined the phenotype and growth characteristics of human mast cells.[3] He found that mast cells form a unique lineage in the hematopoietic cell system.[4][5] In subsequent studies, neoplastic mast cells were characterized.[6][7] The resulting data contributed essentially to the development of diagnostic criteria and the WHO classification of mastocytosis.[8] In 2000, Valent organized a Working Conference on Mastocytosis to implement this classification together with an international consensus group.[9] Since 2002 Valent coordinates the European Competence Network on Mastocytosis that expanded rapidly and provides a useful basis for the development and conduct of studies and activities in the field of mastocytosis.[10] In the forthcoming years, the diagnostic WHO criteria of mastocytosis were validated, adjusted and extended.[11] To discuss these developments, Valent and his team organized additional conferences in Vienna, including a Working Conference on Standards and Standardization of Diagnostic Criteria and Therapies in Mastocytosis[12] and one on the Global Classification of Mast Cell Disorders and Mast Cell Activation Syndromes (2010).[13]

Additional scientific contributions

One additional focus in Valent´s research is the neoplastic stem cell, also termed cancer stem cell in the context of cancer and leukemic stem cell in leukemia contexts. Valent investigates the phenotype of these cells in various hematologic neoplasms and develops concepts predicting the step-wise development of these cells from normal stem cells. The major aim in his research is to identify molecular targets in these cells and to develop more effective (curative) therapies by eliminating these cells in various blood cell disorders, including Acute Myeloid Leukemia, Chronic Myeloid Leukemia,[14] Systemic Mastocytosis[15] and Myelodysplastic Syndromes.[16][17] These studies are primarily conducted in the Ludwig Boltzmann Institute for Hematology and Oncology at the Medical University of Vienna.[18]

Publications

Valent is member in a number of scientific societies and produced over 800 publications in his career, including more than 500 original articles, over 200 review articles and several chapters in world-leading text books in hematology and pathology.[19] In 2001, 2008 and 2016, he also served as author in the WHO Book chapter on mastocytosis.[20] Overall, his publications are cited over 30.000 times and his h-Index (based on Web of Science, March 2020) is 94.[21]

Awards

Valent received several national and international awards, including the Karl Landsteiner-Award of the Austrian Society for Allergy and Immunology, the Paracelsus Award of the Austrian Society for Internal Medicine, the Wilhelm Türk Award of the Austrian Society for Hematology and Oncology, the Theodor-Billroth Medal of the Austrian Medical Association, the Mac Forster Award of the European Society for Clinical Investigation and the Middle European Award for Interdisciplinary Cancer Research.[22]

gollark: Don't you WANT to know of 954 colors?!
gollark: https://xkcd.com/color/rgb/↑ color list
gollark: There definitely was a time where we were doing that, and my autobiographical memory is bad.
gollark: I had foolishly assumed that "lockdown" meant "not going out for school etc.", see.
gollark: It's very heavy!

References
  1. "Peter Valent". Ludwig Boltzmann Institute. 10 December 2008. Retrieved 13 March 2020.
  2. "Peter Valent - Scientific CV". Medizinische Universität Wien. Retrieved 13 March 2020.
  3. Valent, Peter; Bettelheim, P. (1992). "Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol." (52): 333–423. doi:10.1016/s0065-2776(08)60879-2. Cite journal requires |journal= (help)
  4. Valent, Peter; Bettelheim, P. (1992). "Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol." (52): 333–423. doi:10.1016/s0065-2776(08)60879-2. Cite journal requires |journal= (help)
  5. Valent, Peter (1994). "The riddle of the mast cell: kit(CD117)-ligand as the missing link? Immunol Today." (15). doi:10.1016/0167-5699(94)90153-8. Cite journal requires |journal= (help)
  6. Valent, Peter; Schernthaner, GH; Sperr, WR; Fritsch, G; Agis, H; Willheim, M; Bühring, HJ; Orfao, A; Escribano, L (2001). "Variable expression of activation-linked surface antigens on human mast cells in health and disease.". Immunol Rev (179): 74–81. doi:10.1034/j.1600-065x.2001.790108.x.
  7. Valent, Peter; Cerny-Reiterer, S; Herrmann, H; Mirkina, I; George, TI; Sotlar, K; Sperr, WR; Horny, HP (2010). "Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells". Best Pract Res Clin Haematol (23): 369–378. doi:10.1016/j.beha.2010.07.003.
  8. Valent, Peter; Horny, HP; Escribano, L; Longley, BJ; Li, CY; Schwartz, LB; Marone, G; Nuñez, R; Akin, C; Sotlar, K; Sperr, WR; Wolff, K; Parwaresch, RM; Brunning, RD; Austen, KF; Lennert, K; Metcalfe, DD; Vardiman, JW; Bennett, JM (2001). "Diagnostic criteria and classification of mastocytosis: a consensus proposal". Leuk Res (25): 603–625. doi:10.1016/s0145-2126(01)00038-8.
  9. Valent, Peter (1 June 2010). "Classification and response criteria in mastocytosis: is there a need to revise?". Expert Review of Hematology. 3 (3): 247–249. doi:10.1586/ehm.10.20. ISSN 1747-4086. PMID 21082975.
  10. Valent, Peter; Arock, Michel; Bonadonna, Patrizia; Brockow, Knut; Broesby-Olsen, Sigurd; Escribano, Luis; Gleixner, Karoline V.; Grattan, Clive; Hadzijusufovic, Emir; Hägglund, Hans; Hermine, Olivier (1 December 2012). "European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives". Wiener klinische Wochenschrift. 124 (23–24): 807–814. doi:10.1007/s00508-012-0293-z. ISSN 0043-5325. PMID 23179435.
  11. "Peter VALENT, MD". PhD MCCA. Retrieved 8 April 2020.
  12. Valent, P.; Akin, C.; Escribano, L.; Födinger, M.; Hartmann, K.; Brockow, K.; Castells, M.; Sperr, W. R.; Kluin-Nelemans, H. C.; Hamdy, N. A. T.; Lortholary, O. (1 June 2007). "Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria". European Journal of Clinical Investigation. 37 (6): 435–453. doi:10.1111/j.1365-2362.2007.01807.x. ISSN 0014-2972. PMID 17537151.
  13. Valent, Peter; Akin, Cem; Arock, Michel; Brockow, Knut; Butterfield, Joseph H.; Carter, Melody C.; Castells, Mariana; Escribano, Luis; Hartmann, Karin; Lieberman, Philip; Nedoszytko, Boguslaw (2012). "Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal". International Archives of Allergy and Immunology. 157 (3): 215–225. doi:10.1159/000328760. ISSN 1423-0097. PMC 3224511. PMID 22041891.
  14. Valent, Peter; Sadovnik, Irina; Eisenwort, Gregor; Bauer, Karin; Herrmann, Harald; Gleixner, Karoline V.; Schulenburg, Axel; Rabitsch, Werner; Sperr, Wolfgang R.; Wolf, Dominik (29 August 2019). "Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML". International Journal of Molecular Sciences. 20 (17): 4233. doi:10.3390/ijms20174233. ISSN 1422-0067. PMC 6747233. PMID 31470642.
  15. Valent, Peter; Sperr, Wolfgang R.; Akin, Cem (23 December 2010). "How I treat patients with advanced systemic mastocytosis". Blood. 116 (26): 5812–5817. doi:10.1182/blood-2010-08-292144. ISSN 0006-4971. PMID 20855864.
  16. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions, retrieved 15. April 2020 in Ncbi.nlm.nih.gov
  17. Valent, Peter; Orazi, Attilio; Steensma, David P.; Ebert, Benjamin L.; Haase, Detlef; Malcovati, Luca; van de Loosdrecht, Arjan A.; Haferlach, Torsten; Westers, Theresia M.; Wells, Denise A.; Giagounidis, Aristoteles (26 September 2017). "Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions". Oncotarget. 8 (43): 73483–73500. doi:10.18632/oncotarget.19008. ISSN 1949-2553. PMC 5650276. PMID 29088721.
  18. Bockwinkel, Stefanie. "Professor Peter Valent, MD". International CML Foundation. Retrieved 8 April 2020.
  19. "Peter Valent Publication list". Publons. Retrieved 15 April 2020.
  20. Valent, Peter; Akin, Cem; Metcalfe, Dean D. (16 March 2017). "Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts". Blood. 129 (11): 1420–1427. doi:10.1182/blood-2016-09-731893. ISSN 0006-4971. PMC 5356454. PMID 28031180.
  21. "Peter Valent". Publons. Retrieved 8 April 2020.
  22. "Univ.-Prof. Dr. Peter Valent". Medizinische Universität Wien. Retrieved 8 April 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.